Biomechanical and Microstructural Properties of Ascending Aortic Aneurysms
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · May 2, 2017
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding the physical and structural characteristics of thoracic aortic aneurysms, which are bulges in the aorta caused by a weakening of the artery wall. The main goal is to create a better tool for diagnosing these aneurysms by studying their biomechanics and microstructure. This is important because current methods may not provide enough information to prevent serious complications, such as aortic rupture, which can be life-threatening.
If you or a loved one has a thoracic aortic aneurysm, whether you have symptoms or not, you might be eligible to participate in this study. The trial is open to all genders and is currently recruiting participants aged 65 to 74. Those who have experienced a ruptured aneurysm and are undergoing emergency surgery may also qualify. Participants will be asked to provide informed consent and may undergo tests to help researchers gather tissue samples for study. This research aims to improve how we diagnose and treat this serious condition, ultimately helping to save lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients suffering from thoracic aortic aneurysms (ATAA), asymptomatic or symptomatic.
- • Patients with ruptured ATAA undergoing an emergency surgery.
- • Signed informed consent.
- Exclusion Criteria:
- • Patients with ruptured ATAA due to trauma.
- • The presence of any aneurysm feature that will prevent the collection of tissue samples suitable for the biomechanical and microstructural studies.
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Belgium
Patients applied
Trial Officials
Bart Meuris, PhD
Principal Investigator
UZ Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials